Peptide·plain sequence-like

Thymalfasin

ATLPC0003634

SDAAVDTSSEITTKDLKEKKEVVEEAEN

Routes

Compare in workbench Download release API JSON

Length
28 aa
Monoisotopic mass
3064.5 Da
Net charge @ pH 7.4
-5.00
Isoelectric point
3.99
GRAVY
-1.029

Coveragecounts only · not riskATLPC0003634

Measurements
6
Endpoints
5
Domains
3/5
Products
1

1 stability measurement
No clearance evidence
Product-level review pending
1 liability motif

Jump to domain

Open the matching evidence section below

All evidence index · 6

Exposure / Absorption

4 measurements

Distribution / Barrier

1 measurement

Metabolic & Proteolytic Stability

1 measurement

Excretion / Persistence

No evidence

Toxicity / Safety

No evidence

Sequence & molecular identity

1 forms

Reviewed sequence, peptidoform forms, chemical representation, 3D references, and covalent topology used to interpret this peptide identity.

Sequence & peptidoform

Identity summaryCanonical sequence only

Identity status: Canonical sequence only
Residues: 28
Peptidoform features: 0
Documented molecular forms: 1
Representations: 2

Documented molecular forms1 form linked to this peptide identity

Form	Topology	Modifications	Connections	Representations	Measurements
ATLPF0003963	—	—	—	Notation only	—

Residue view

Residue display

28 residues

S1D2A3A4V5D6T7S8S9E10I11T12T13K14D15L16K17E18K19K20E21V22V23E24E25A26E27N28

Side-chain classNonpolarPolarBasic (+)Acidic (−)Modified

Soft tints mark standard side-chain classes for scanning. Primary emphasis is reserved for reported modifications, termini, secondary-structure tracks, and topology links.

Peptidoform features

Features are shown only when a reported notation or topology record supports them.

No terminal modification, residue-level marker, disulfide, staple, coordination, or other topology signal is currently available.

Structure & chemistry

Chemical representationsequence / HELM only

Representation class

How the current release can interpret this identity chemically.

plain sequence-like

Parent-residue sequence

Residue string used for positional interpretation when available.

SDAAVDTSSEITTKDLKEKKEVVEEAEN

HELM

Polymer notation for modified peptide representation when available.

Not available

SMILES

Chemical graph string used for atom-level 2D depiction when available.

Not available

No atom-level graph

A reviewed SMILES is required before a 2D molecular depiction can be shown. Sequence and HELM remain useful for identity interpretation, but they do not replace a chemical graph.

3D structure references2 references

Structure reference·

3D coordinates·Sequence matchexperimental

Sequence match·reference selected·identity 100.0%·confidence experimental

Link	Method	Confidence	Match
Open	Sequence match	experimental	100.0% identity
Open	Sequence match	experimental	100.0% identity

Covalent topology & modificationsnone

Exact topology not established

No reviewed form-level topology or residue-level connection annotation is attached to this peptide in the current release. This is not evidence that every molecular form is linear or unmodified.

Physicochemical profile

4 descriptors

Computed sequence-derived descriptors and any measured physicochemical evidence such as lipophilicity. Computed values are interpretation aids, not experimental ADMET measurements.

Core descriptors28 aa · pI 4.0 · GRAVY -1.03

Length: 28 aa
Monoisotopic mass: 3064.49 Da
Average mass: 3066.28 Da
Net charge at pH 7.4: -5.00
Estimated pI: 3.99
GRAVY: -1.029
KD-positive residues: 28.6%
Aromatic residues: 0.0%

Developability interpretation

Ionization context: pH 7.4 separated from pI
Hydrophobicity balance: Leans hydrophilic
Amphipathic moment (μH): 1.07
Computation boundary: Standard-sequence only

Charge & residue composition

pH charge context

Modeled net charge across common formulation and assay pH checkpoints.

pH 2

4.89

pH 5

-4.07

pH 6

-4.90

pH 7.4

-5.06

pH 9

-5.78

pH 12

-9.76

Residue-class composition

Grouped composition is often more interpretable than a long amino-acid list.

Acidic (D,E)

9 · 32.1%

Basic (K,R,H)

4 · 14.3%

Polar uncharged (N,Q,S,T)

7 · 25.0%

Hydrophobic aliphatic (A,V,I,L,M)

8 · 28.6%

Top residues

E621.4%K414.3%A310.7%D310.7%S310.7%T310.7%V310.7%N13.6%

Hydropathy & amphipathic windows

Hydropathy windows

Seven-residue sliding windows expose local patches hidden by whole-sequence GRAVY.

Most hydrophobic window

3-9

AAVDTSS

GRAVY 0.286

Most hydrophilic window

14-20

KDLKEKK

GRAVY -2.686

22 local hydropathy windows scanned. A local patch is context for solubility, adsorption, and membrane interaction review, not a standalone endpoint.

Amphipathic-window scan

Top alpha-helix hydrophobic-moment windows across 12, 15, 18, and 21 residues.

12 aa window

17-28

KEKKEVVEEAEN

μH 1.60 · charge -2.0

12 aa window

14-25

KDLKEKKEVVEE

μH 1.49 · charge -1.0

12 aa window

16-27

LKEKKEVVEEAE

μH 1.43 · charge -2.0

15 aa window

14-28

KDLKEKKEVVEEAEN

μH 1.41 · charge -2.0

12 aa window

15-26

DLKEKKEVVEEA

μH 1.30 · charge -2.0

Sequence-liability cues

Sequence-liability notes

Motifs are review prompts for formulation or CMC interpretation; they are not degradation predictions.

Asp isomerization motif

DT · pos 6

Asp-containing motifs can merit review for isomerization or related degradation pathways.

Alpha-helix amphipathic projection

Helical wheel · Edmundson projection

μ_H = 1.07100°/residue · 28 aa

Hydrophobic moment1.07

Mean K-D hydropathy-1.03

Approx. net charge-5

Projection angle100° / residue

The pale sector marks the direction of the hydrophobic face inferred from μ_H. This is a projection assumption, not a measured fold.

HydrophobicAromaticPolarBasic +Acidic −Specialhydrophobic faceμ_H arrow → hydrophobic face

The projection assumes an α-helix conformation; a long μ_H arrow indicates an amphipathic helix, common in antimicrobial peptides.

Method notes

Charge model: side-chain pKa D 3.9, E 4.1, C 8.5, Y 10.1, H 6.5, K 10.8, R 12.5 with EMBOSS termini. pI is estimated by binary search on modeled net charge. Hydropathy uses Kyte-Doolittle values; hydrophobic moment follows the Eisenberg alpha-helix vector-sum convention. When the basis is a parent-residue sequence, modified chemistry is intentionally not inferred.

Computed developability descriptors

Deterministic descriptors computed from the reviewed sequence or chemical structure (RDKit), each anchored to a literature method. These are computed estimates for developability interpretation — not experimental measurements — and are validated against independent reference implementations.

Sequence-derived

Computed from the standard parent-residue sequence; protein-origin metrics defined at any length.

Aliphatic index

69.64

Instability index

28.1

At or below 40 — predicted stable in vitro.

Boman index

3.08 kcal/mol

Above 2.48 — elevated potential protein-binding.

Molar extinction coefficient (280 nm)

0 M⁻¹·cm⁻¹

A280 (1 g/L) ≈ 0.00

Structure-derived descriptors are not shown because this identity has no resolved chemical structure (SMILES). This is a known coverage gap for disulfide-rich and unresolved peptidoforms, not a computation error.

Exposure / Absorption

4 records

What evidence describes systemic exposure or absorption?

Evidence records

Complete canonical measurements and observations attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Matched-context analysis

Quantitative results that may be analysed only with scientifically compatible records.

Reported-result review

Qualitative, narrative, or review-first results interpreted in their source context.

Endpoints in scopeTmax Cmax AUC

Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis

Quantitative results whose endpoint and context must still be matched before analysis.

Interpret as reported

Qualitative, narrative, or review-first findings preserved in source context.

Supporting context only

Reference, label, clinical, or supporting context for interpretation.

Review before analysis

Records whose present structure does not establish a safe analysis role.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

AUC1 record · 1 matched-context · 0 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	95-267 μg*h/L	Eligible when experimental context matches	ELISA serum concentration assay; model-independent PK analysis; manual extraction from PubMed abstract with FDA PCAC review corroboration · human · serum	Result: Interval measurement · Molecular form: not reported · Route: subcutaneous · Dose/window: single-dose and 5-day multiple-dose PK · Source: Primary reference linked	Reference

Cmax1 record · 1 matched-context · 0 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	30-80 μg/L	Eligible when experimental context matches	ELISA serum concentration assay; model-independent PK analysis; manual extraction from PubMed abstract with FDA PCAC review corroboration · human · serum	Result: Interval measurement · Molecular form: not reported · Route: subcutaneous · Dose/window: single-dose and 5-day multiple-dose PK · Source: Primary reference linked	Reference

Tmax2 records · 1 matched-context · 1 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	0.67-2 h 2412-7200 seconds	Eligible when experimental context matches	ELISA serum concentration assay; model-independent PK analysis; manual extraction from PubMed abstract with FDA PCAC review corroboration · human · serum	Result: Interval measurement · Molecular form: not reported · Route: subcutaneous · Dose/window: single-dose and 5-day multiple-dose PK · Source: Primary reference linked	Reference
2	~ 2 hours ~ 7200 seconds	Use only explicitly reported fields	Not specified	Result: Approximate quantitative measurement · Molecular form: not reported · Route: IM, SC · 13 · Thymalfasin · exact product name match · exact or normalized match · Source: Primary reference linked	Source record

Distribution / Barrier

1 records

What is known about distribution, binding, permeability, or barrier crossing?

Evidence records

Complete canonical measurements and observations attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Matched-context analysis

Quantitative results that may be analysed only with scientifically compatible records.

Reported-result review

Qualitative, narrative, or review-first results interpreted in their source context.

Endpoints in scopeVd

Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis

Quantitative results whose endpoint and context must still be matched before analysis.

Interpret as reported

Qualitative, narrative, or review-first findings preserved in source context.

Supporting context only

Reference, label, clinical, or supporting context for interpretation.

Review before analysis

Records whose present structure does not establish a safe analysis role.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Vd1 record · 1 matched-context · 0 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	30-40 L	Eligible when experimental context matches	ELISA serum concentration assay; model-independent PK analysis; manual extraction from PubMed abstract with FDA PCAC review corroboration · human · serum	Result: Interval measurement · Molecular form: not reported · Route: subcutaneous · Dose/window: single-dose and 5-day multiple-dose PK · Source: Primary reference linked	Reference

Barrier and permeability assay context

PAMPA, Caco-2, MDCK/RRCK, and BBB findings are assay/model contexts under Distribution / Barrier. They should not be read as interchangeable measurements.

PAMPA

artificial membrane

Caco-2

cell monolayer

MDCK

cell monolayer

RRCK

cell monolayer

BBB

barrier evidence

Metabolic & Proteolytic Stability

1 records

How stable is the peptide in biological matrices or protease systems?

Evidence records

Complete canonical measurements and observations attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Matched-context analysis

Quantitative results that may be analysed only with scientifically compatible records.

Reported-result review

Qualitative, narrative, or review-first results interpreted in their source context.

Endpoints in scopeSerum/plasma stability

Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis

Quantitative results whose endpoint and context must still be matched before analysis.

Interpret as reported

Qualitative, narrative, or review-first findings preserved in source context.

Supporting context only

Reference, label, clinical, or supporting context for interpretation.

Review before analysis

Records whose present structure does not establish a safe analysis role.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Serum/plasma stability1 record · 1 matched-context · 0 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	127 ±11 minutes 7620 seconds	Eligible when experimental context matches	HPLC · Heparinized rabbit plasma	Result: Reported point value · Molecular form: ATLPF0040993 · Rabbit plasma proteases · in vitro · Source: Primary reference linked	Reference

Evidence landscape

6 records

Cross-domain evidence distribution and measurement-level detail; the domain modules above show evidence in context, and every row remains available for audit here.

Evidence landscape

A cross-domain view of evidence volume, scientifically permitted analysis use, and source traceability.

ADMET domain

Eligible when context matches

Interpret as reported

Supporting context only

Review before analysis

Exposure / Absorption

4 evidence records

Distribution / Barrier

1 evidence record

Metabolic & Proteolytic Stability

1 evidence record

Excretion / Persistence

0 evidence records

Toxicity / Safety

0 evidence records

Endpoint distribution

Top evidence-bearing endpoint questions.

Time To Max Concentration

Area Under Curve

Max Concentration

Serum Plasma Stability

Volume Of Distribution

Assay context

Broad context buckets, useful before comparing values.

In vivo / route

Clinical / product

Matrix / stability

Traceability

Reference-link availability for measurement-level audit.

Linked reference

Not linked

All evidence index

Every evidence record remains available for audit and drilldown. Counts describe evidence volume, not confidence.

DomainAnalysis useReferenceSpeciesMatrixRoute

#	ADMET domain	Endpoint	Reported value	Result type	Analysis use	Assay / model	Condition	Reference
1	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	127 ±11 minutes 7,620 seconds	Reported point value	Eligible when experimental context matches	HPLC · Heparinized rabbit plasma	Protease: Rabbit plasma proteases · in vitro	Reference Primary reference linked
2	Exposure / Absorption Exposure	Time To Max Concentration	~ 2 hours ~ 7,200 seconds	Approximate quantitative measurement	Use only explicitly reported fields	Not specified	Route: IM, SC	Source record Primary reference linked
3	Exposure / Absorption Exposure	Max Concentration	30-80 μg/L	Interval measurement	Eligible when experimental context matches	ELISA serum concentration assay; model-independent PK analysis; manual extraction from PubMed abstract with FDA PCAC re...	Route: subcutaneous · Dose/window: single-dose and 5-day multiple-dose PK · Human healthy-volunteer crossover PK study comparing three subcutaneous thymosin alpha1 formulations. The public...	Reference Primary reference linked
4	Exposure / Absorption Exposure	Area Under Curve	95-267 μg*h/L	Interval measurement	Eligible when experimental context matches	ELISA serum concentration assay; model-independent PK analysis; manual extraction from PubMed abstract with FDA PCAC re...	Route: subcutaneous · Dose/window: single-dose and 5-day multiple-dose PK · Human healthy-volunteer crossover PK study comparing three subcutaneous thymosin alpha1 formulations. The public...	Reference Primary reference linked
5	Exposure / Absorption Exposure	Time To Max Concentration	0.67-2 h 2,412-7,200 seconds	Interval measurement	Eligible when experimental context matches	ELISA serum concentration assay; model-independent PK analysis; manual extraction from PubMed abstract with FDA PCAC re...	Route: subcutaneous · Dose/window: single-dose and 5-day multiple-dose PK · Human healthy-volunteer crossover PK study comparing three subcutaneous thymosin alpha1 formulations. The public...	Reference Primary reference linked
6	Distribution / Barrier Distribution	Volume Of Distribution	30-40 L	Interval measurement	Eligible when experimental context matches	ELISA serum concentration assay; model-independent PK analysis; manual extraction from PubMed abstract with FDA PCAC re...	Route: subcutaneous · Dose/window: single-dose and 5-day multiple-dose PK · Human healthy-volunteer crossover PK study comparing three subcutaneous thymosin alpha1 formulations. The public...	Reference Primary reference linked

1–6 / 6

Product context

1 products

Product-level route, label, and clinical context that frames peptide-level evidence. A peptide-level summary only; product pages keep the full drilldown.

Summary1 linked product

Linked products: 1
Label context: None
Clinical trials: 35
Safety label cues: None

Linked products1 shown

Thymalfasin

Tα1 (Thymosin α1)Thymosin α1Tα1TÎ±1 (Thymosin Î±1)

Peptide-product match

Reviewed peptide match

Route / product class

Subcutaneous

Clinical context

35 trial records · 10 exact intervention matches · latest 2026-03-19

Label safety context

No label safety cue linked

View product

Identity & reference map

6 sources

Reference-level support for checking reported names, sequence notation, and peptide identity agreement.

Summary3 reference groups

Identity type: canonical sequence
Reported notation: 1
Reference groups: 3
Measurements: 6
ATL peptide ID: ATLPC0003634

Identity concordance

Exact reported notation

Reported sequence string matches the current peptide notation.

0 / 6

Parent-residue compatible

Reported notation differs, but resolves to the same parent-residue display.

0 / 6

Different notation

Reported notation does not resolve to the current display sequence.

1 / 6

Source sequence not captured

No source-specific sequence was captured for comparison; this is not interpreted as agreement or disagreement.

5 / 6

Reported sequence notation

Different1 reference

Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN

Current identity

SDAAVDTSSEITTKDLKEKKEVVEEAEN

Reported names

No distinct human-readable aliases are exposed.

Reference map3 reference groups

Reference map

Grouped by reference link, with endpoint scope and reported identity kept visible.

Reference	Supports	Reported identity	Records
Reference Open	DistributionExposure Area Under Curve, Max Concentration, Time To Max Concentration, Volume Of Distribution	No reported alias	4 identity 4 evidence
Reference Open	Stability Serum Plasma Stability	No reported alias	1 identity 1 evidence
Source record Open	Exposure Time To Max Concentration	No reported alias Ac-SDAAVDTSSEITTKDLKEKKEVVEEAENdifferent	1 identity 1 evidence

Data access & reproducibility

Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.

Record scopePublic release

ATL peptide ID: ATLPC0003634
Identity type: canonical sequence
ADMET endpoints: 5
Evidence records: 6
Reference groups: 3
Release view: Public release

Data access

Structured peptide profile

JSON

Peptide-specific profile used by this page, including identity and evidence context.

Open JSON

Peptide catalogue

TSV

Complete frozen peptide table. Filter the ATL peptide ID column locally to isolate this record.

Download catalogue

Measurement catalogue

TSV

Complete frozen measurement table. Join or filter by ATL peptide ID for peptide-level analysis.

Download measurements

Programmatic access

The request returns the same structured peptide record used by this profile. The tabular downloads are complete frozen release tables and should be filtered locally by ATL peptide ID.

Open endpoint

GET /api/v1/peptides/ATLPC0003634

open

curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0003634' \
  -H 'accept: application/json' \
  -H 'X-Visibility: public_release'

Form

Topology

Modifications

Connections

Representations

Measurements

ATLPF0003963

—

Notation only

—

Link

Method

Confidence

Match

Open

Sequence match

experimental

100.0% identity

Open

Sequence match

experimental

100.0% identity

Value

Analysis use

Assay / model

Result context

Reference

95-267 μg*h/L

Eligible when experimental context matches

ELISA serum concentration assay; model-independent PK analysis; manual extraction from PubMed abstract with FDA PCAC review corroboration · human · serum

Result: Interval measurement · Molecular form: not reported · Route: subcutaneous · Dose/window: single-dose and 5-day multiple-dose PK · Source: Primary reference linked

Reference

Value

Analysis use

Assay / model

Result context

Reference

30-80 μg/L

Eligible when experimental context matches

ELISA serum concentration assay; model-independent PK analysis; manual extraction from PubMed abstract with FDA PCAC review corroboration · human · serum

Result: Interval measurement · Molecular form: not reported · Route: subcutaneous · Dose/window: single-dose and 5-day multiple-dose PK · Source: Primary reference linked

Reference

Value

Analysis use

Assay / model

Result context

Reference

0.67-2 h

2412-7200 seconds

Eligible when experimental context matches

ELISA serum concentration assay; model-independent PK analysis; manual extraction from PubMed abstract with FDA PCAC review corroboration · human · serum

Result: Interval measurement · Molecular form: not reported · Route: subcutaneous · Dose/window: single-dose and 5-day multiple-dose PK · Source: Primary reference linked

Reference

~ 2 hours

~ 7200 seconds

Use only explicitly reported fields

Not specified

Result: Approximate quantitative measurement · Molecular form: not reported · Route: IM, SC · 13 · Thymalfasin · exact product name match · exact or normalized match · Source: Primary reference linked

Source record

Value

Analysis use

Assay / model

Result context

Reference

30-40 L

Eligible when experimental context matches

ELISA serum concentration assay; model-independent PK analysis; manual extraction from PubMed abstract with FDA PCAC review corroboration · human · serum

Result: Interval measurement · Molecular form: not reported · Route: subcutaneous · Dose/window: single-dose and 5-day multiple-dose PK · Source: Primary reference linked

Reference

Value

Analysis use

Assay / model

Result context

Reference

127 ±11 minutes

7620 seconds

Eligible when experimental context matches

HPLC · Heparinized rabbit plasma

Result: Reported point value · Molecular form: ATLPF0040993 · Rabbit plasma proteases · in vitro · Source: Primary reference linked

Reference

ADMET domain

Endpoint

Reported value

Result type

Analysis use

Assay / model

Condition

Reference

Metabolic & Proteolytic Stability

Stability

Serum Plasma Stability

127 ±11 minutes

7,620 seconds

Reported point value

Eligible when experimental context matches

HPLC · Heparinized rabbit plasma

Protease: Rabbit plasma proteases · in vitro

Reference

Primary reference linked

Exposure / Absorption

Exposure

Time To Max Concentration

~ 2 hours

~ 7,200 seconds

Approximate quantitative measurement

Use only explicitly reported fields

Not specified

Route: IM, SC

Source record

Primary reference linked

Exposure / Absorption

Exposure

Max Concentration

30-80 μg/L

Interval measurement

Eligible when experimental context matches

ELISA serum concentration assay; model-independent PK analysis; manual extraction from PubMed abstract with FDA PCAC re...

Route: subcutaneous · Dose/window: single-dose and 5-day multiple-dose PK · Human healthy-volunteer crossover PK study comparing three subcutaneous thymosin alpha1 formulations. The public...

Reference

Primary reference linked

Exposure / Absorption

Exposure

Area Under Curve

95-267 μg*h/L

Interval measurement

Eligible when experimental context matches

ELISA serum concentration assay; model-independent PK analysis; manual extraction from PubMed abstract with FDA PCAC re...

Route: subcutaneous · Dose/window: single-dose and 5-day multiple-dose PK · Human healthy-volunteer crossover PK study comparing three subcutaneous thymosin alpha1 formulations. The public...

Reference

Primary reference linked

Exposure / Absorption

Exposure

Time To Max Concentration

0.67-2 h

2,412-7,200 seconds

Interval measurement

Eligible when experimental context matches

ELISA serum concentration assay; model-independent PK analysis; manual extraction from PubMed abstract with FDA PCAC re...

Route: subcutaneous · Dose/window: single-dose and 5-day multiple-dose PK · Human healthy-volunteer crossover PK study comparing three subcutaneous thymosin alpha1 formulations. The public...

Reference

Primary reference linked

Distribution / Barrier

Distribution

Volume Of Distribution

30-40 L

Interval measurement

Eligible when experimental context matches

ELISA serum concentration assay; model-independent PK analysis; manual extraction from PubMed abstract with FDA PCAC re...

Route: subcutaneous · Dose/window: single-dose and 5-day multiple-dose PK · Human healthy-volunteer crossover PK study comparing three subcutaneous thymosin alpha1 formulations. The public...

Reference

Primary reference linked

Reference

Supports

Reported identity

Records

Reference

Open

DistributionExposure

Area Under Curve, Max Concentration, Time To Max Concentration, Volume Of Distribution

No reported alias

4 identity

4 evidence

Reference

Open

Stability

Serum Plasma Stability

No reported alias

1 identity

1 evidence

Source record

Open

Exposure

Time To Max Concentration

No reported alias

Ac-SDAAVDTSSEITTKDLKEKKEVVEEAENdifferent

1 identity

1 evidence